ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antibody-drug Conjugate for Cancer Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-28Z6647
Home | Market Reports | Health| Health Conditions| Cancer
Global Antibody drug Conjugate for Cancer Market Insights Forecast to 2028
BUY CHAPTERS

Global Antibody-drug Conjugate for Cancer Market Research Report 2025

Code: QYRE-Auto-28Z6647
Report
July 2025
Pages:75
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Gilead Sciences
Roche
Pfizer Inc
Takeda
Seagen
Innate Pharma
Astrazeneca plc
GSK
Rakuten Medical

Antibody-drug Conjugate for Cancer Market Size

The global market for Antibody-drug Conjugate for Cancer was valued at US$ 933 million in the year 2024 and is projected to reach a revised size of US$ 1281 million by 2031, growing at a CAGR of 4.7% during the forecast period.

Antibody-drug Conjugate for Cancer Market

Antibody-drug Conjugate for Cancer Market

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibody-drug Conjugate for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-drug Conjugate for Cancer.
The Antibody-drug Conjugate for Cancer market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody-drug Conjugate for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody-drug Conjugate for Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Antibody-drug Conjugate for Cancer Market Report

Report Metric Details
Report Name Antibody-drug Conjugate for Cancer Market
Accounted market size in year US$ 933 million
Forecasted market size in 2031 US$ 1281 million
CAGR 4.7%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospital
  • Pharmacy
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Gilead Sciences, Roche, Pfizer, Takeda, Seagen, Innate Pharma, AstraZeneca, GSK, Rakuten Medical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Antibody-drug Conjugate for Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Antibody-drug Conjugate for Cancer Market growing?

Ans: The Antibody-drug Conjugate for Cancer Market witnessing a CAGR of 4.7% during the forecast period 2025-2031.

What is the Antibody-drug Conjugate for Cancer Market size in 2031?

Ans: The Antibody-drug Conjugate for Cancer Market size in 2031 will be US$ 1281 million.

Who are the main players in the Antibody-drug Conjugate for Cancer Market report?

Ans: The main players in the Antibody-drug Conjugate for Cancer Market are Gilead Sciences, Roche, Pfizer, Takeda, Seagen, Innate Pharma, AstraZeneca, GSK, Rakuten Medical

What are the Application segmentation covered in the Antibody-drug Conjugate for Cancer Market report?

Ans: The Applications covered in the Antibody-drug Conjugate for Cancer Market report are Hospital, Pharmacy, Other

What are the Type segmentation covered in the Antibody-drug Conjugate for Cancer Market report?

Ans: The Types covered in the Antibody-drug Conjugate for Cancer Market report are Hematological Malignancies Drugs, Solid Tumor Drugs

Recommended Reports

Cancer Drug Therapies

Antibody-based Therapeutics

Emerging Cancer Solutions

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Hematological Malignancies Drugs
1.2.3 Solid Tumor Drugs
1.3 Market by Application
1.3.1 Global Antibody-drug Conjugate for Cancer Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody-drug Conjugate for Cancer Market Perspective (2020-2031)
2.2 Global Antibody-drug Conjugate for Cancer Growth Trends by Region
2.2.1 Global Antibody-drug Conjugate for Cancer Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antibody-drug Conjugate for Cancer Historic Market Size by Region (2020-2025)
2.2.3 Antibody-drug Conjugate for Cancer Forecasted Market Size by Region (2026-2031)
2.3 Antibody-drug Conjugate for Cancer Market Dynamics
2.3.1 Antibody-drug Conjugate for Cancer Industry Trends
2.3.2 Antibody-drug Conjugate for Cancer Market Drivers
2.3.3 Antibody-drug Conjugate for Cancer Market Challenges
2.3.4 Antibody-drug Conjugate for Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody-drug Conjugate for Cancer Players by Revenue
3.1.1 Global Top Antibody-drug Conjugate for Cancer Players by Revenue (2020-2025)
3.1.2 Global Antibody-drug Conjugate for Cancer Revenue Market Share by Players (2020-2025)
3.2 Global Antibody-drug Conjugate for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibody-drug Conjugate for Cancer Revenue
3.4 Global Antibody-drug Conjugate for Cancer Market Concentration Ratio
3.4.1 Global Antibody-drug Conjugate for Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody-drug Conjugate for Cancer Revenue in 2024
3.5 Global Key Players of Antibody-drug Conjugate for Cancer Head office and Area Served
3.6 Global Key Players of Antibody-drug Conjugate for Cancer, Product and Application
3.7 Global Key Players of Antibody-drug Conjugate for Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody-drug Conjugate for Cancer Breakdown Data by Type
4.1 Global Antibody-drug Conjugate for Cancer Historic Market Size by Type (2020-2025)
4.2 Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Type (2026-2031)
5 Antibody-drug Conjugate for Cancer Breakdown Data by Application
5.1 Global Antibody-drug Conjugate for Cancer Historic Market Size by Application (2020-2025)
5.2 Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antibody-drug Conjugate for Cancer Market Size (2020-2031)
6.2 North America Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antibody-drug Conjugate for Cancer Market Size by Country (2020-2025)
6.4 North America Antibody-drug Conjugate for Cancer Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody-drug Conjugate for Cancer Market Size (2020-2031)
7.2 Europe Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2020-2025)
7.4 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size (2020-2031)
8.2 Asia-Pacific Antibody-drug Conjugate for Cancer Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size by Region (2020-2025)
8.4 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody-drug Conjugate for Cancer Market Size (2020-2031)
9.2 Latin America Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2020-2025)
9.4 Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size (2020-2031)
10.2 Middle East & Africa Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2020-2025)
10.4 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Details
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences Antibody-drug Conjugate for Cancer Introduction
11.1.4 Gilead Sciences Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025)
11.1.5 Gilead Sciences Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Antibody-drug Conjugate for Cancer Introduction
11.2.4 Roche Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025)
11.2.5 Roche Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Antibody-drug Conjugate for Cancer Introduction
11.3.4 Pfizer Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025)
11.3.5 Pfizer Recent Development
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Antibody-drug Conjugate for Cancer Introduction
11.4.4 Takeda Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025)
11.4.5 Takeda Recent Development
11.5 Seagen
11.5.1 Seagen Company Details
11.5.2 Seagen Business Overview
11.5.3 Seagen Antibody-drug Conjugate for Cancer Introduction
11.5.4 Seagen Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025)
11.5.5 Seagen Recent Development
11.6 Innate Pharma
11.6.1 Innate Pharma Company Details
11.6.2 Innate Pharma Business Overview
11.6.3 Innate Pharma Antibody-drug Conjugate for Cancer Introduction
11.6.4 Innate Pharma Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025)
11.6.5 Innate Pharma Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Antibody-drug Conjugate for Cancer Introduction
11.7.4 AstraZeneca Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025)
11.7.5 AstraZeneca Recent Development
11.8 GSK
11.8.1 GSK Company Details
11.8.2 GSK Business Overview
11.8.3 GSK Antibody-drug Conjugate for Cancer Introduction
11.8.4 GSK Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025)
11.8.5 GSK Recent Development
11.9 Rakuten Medical
11.9.1 Rakuten Medical Company Details
11.9.2 Rakuten Medical Business Overview
11.9.3 Rakuten Medical Antibody-drug Conjugate for Cancer Introduction
11.9.4 Rakuten Medical Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025)
11.9.5 Rakuten Medical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Gilead Sciences
Roche
Pfizer Inc
Takeda
Seagen
Innate Pharma
Astrazeneca plc
GSK
Rakuten Medical
List of Tables
 Table 1. Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Hematological Malignancies Drugs
 Table 3. Key Players of Solid Tumor Drugs
 Table 4. Global Antibody-drug Conjugate for Cancer Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Antibody-drug Conjugate for Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Antibody-drug Conjugate for Cancer Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Antibody-drug Conjugate for Cancer Market Share by Region (2020-2025)
 Table 8. Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Antibody-drug Conjugate for Cancer Market Share by Region (2026-2031)
 Table 10. Antibody-drug Conjugate for Cancer Market Trends
 Table 11. Antibody-drug Conjugate for Cancer Market Drivers
 Table 12. Antibody-drug Conjugate for Cancer Market Challenges
 Table 13. Antibody-drug Conjugate for Cancer Market Restraints
 Table 14. Global Antibody-drug Conjugate for Cancer Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Antibody-drug Conjugate for Cancer Market Share by Players (2020-2025)
 Table 16. Global Top Antibody-drug Conjugate for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-drug Conjugate for Cancer as of 2024)
 Table 17. Ranking of Global Top Antibody-drug Conjugate for Cancer Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Antibody-drug Conjugate for Cancer Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Antibody-drug Conjugate for Cancer, Headquarters and Area Served
 Table 20. Global Key Players of Antibody-drug Conjugate for Cancer, Product and Application
 Table 21. Global Key Players of Antibody-drug Conjugate for Cancer, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Antibody-drug Conjugate for Cancer Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2020-2025)
 Table 25. Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Type (2026-2031)
 Table 27. Global Antibody-drug Conjugate for Cancer Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Application (2020-2025)
 Table 29. Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Antibody-drug Conjugate for Cancer Revenue Market Share by Application (2026-2031)
 Table 31. North America Antibody-drug Conjugate for Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Antibody-drug Conjugate for Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Antibody-drug Conjugate for Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Antibody-drug Conjugate for Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Antibody-drug Conjugate for Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Antibody-drug Conjugate for Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Antibody-drug Conjugate for Cancer Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Antibody-drug Conjugate for Cancer Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Antibody-drug Conjugate for Cancer Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Antibody-drug Conjugate for Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Antibody-drug Conjugate for Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Gilead Sciences Company Details
 Table 47. Gilead Sciences Business Overview
 Table 48. Gilead Sciences Antibody-drug Conjugate for Cancer Product
 Table 49. Gilead Sciences Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025) & (US$ Million)
 Table 50. Gilead Sciences Recent Development
 Table 51. Roche Company Details
 Table 52. Roche Business Overview
 Table 53. Roche Antibody-drug Conjugate for Cancer Product
 Table 54. Roche Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025) & (US$ Million)
 Table 55. Roche Recent Development
 Table 56. Pfizer Company Details
 Table 57. Pfizer Business Overview
 Table 58. Pfizer Antibody-drug Conjugate for Cancer Product
 Table 59. Pfizer Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025) & (US$ Million)
 Table 60. Pfizer Recent Development
 Table 61. Takeda Company Details
 Table 62. Takeda Business Overview
 Table 63. Takeda Antibody-drug Conjugate for Cancer Product
 Table 64. Takeda Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025) & (US$ Million)
 Table 65. Takeda Recent Development
 Table 66. Seagen Company Details
 Table 67. Seagen Business Overview
 Table 68. Seagen Antibody-drug Conjugate for Cancer Product
 Table 69. Seagen Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025) & (US$ Million)
 Table 70. Seagen Recent Development
 Table 71. Innate Pharma Company Details
 Table 72. Innate Pharma Business Overview
 Table 73. Innate Pharma Antibody-drug Conjugate for Cancer Product
 Table 74. Innate Pharma Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025) & (US$ Million)
 Table 75. Innate Pharma Recent Development
 Table 76. AstraZeneca Company Details
 Table 77. AstraZeneca Business Overview
 Table 78. AstraZeneca Antibody-drug Conjugate for Cancer Product
 Table 79. AstraZeneca Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025) & (US$ Million)
 Table 80. AstraZeneca Recent Development
 Table 81. GSK Company Details
 Table 82. GSK Business Overview
 Table 83. GSK Antibody-drug Conjugate for Cancer Product
 Table 84. GSK Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025) & (US$ Million)
 Table 85. GSK Recent Development
 Table 86. Rakuten Medical Company Details
 Table 87. Rakuten Medical Business Overview
 Table 88. Rakuten Medical Antibody-drug Conjugate for Cancer Product
 Table 89. Rakuten Medical Revenue in Antibody-drug Conjugate for Cancer Business (2020-2025) & (US$ Million)
 Table 90. Rakuten Medical Recent Development
 Table 91. Research Programs/Design for This Report
 Table 92. Key Data Information from Secondary Sources
 Table 93. Key Data Information from Primary Sources
 Table 94. Authors List of This Report


List of Figures
 Figure 1. Antibody-drug Conjugate for Cancer Picture
 Figure 2. Global Antibody-drug Conjugate for Cancer Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Antibody-drug Conjugate for Cancer Market Share by Type: 2024 VS 2031
 Figure 4. Hematological Malignancies Drugs Features
 Figure 5. Solid Tumor Drugs Features
 Figure 6. Global Antibody-drug Conjugate for Cancer Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Antibody-drug Conjugate for Cancer Market Share by Application: 2024 VS 2031
 Figure 8. Hospital Case Studies
 Figure 9. Pharmacy Case Studies
 Figure 10. Other Case Studies
 Figure 11. Antibody-drug Conjugate for Cancer Report Years Considered
 Figure 12. Global Antibody-drug Conjugate for Cancer Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 13. Global Antibody-drug Conjugate for Cancer Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Antibody-drug Conjugate for Cancer Market Share by Region: 2024 VS 2031
 Figure 15. Global Antibody-drug Conjugate for Cancer Market Share by Players in 2024
 Figure 16. Global Top Antibody-drug Conjugate for Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-drug Conjugate for Cancer as of 2024)
 Figure 17. The Top 10 and 5 Players Market Share by Antibody-drug Conjugate for Cancer Revenue in 2024
 Figure 18. North America Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 19. North America Antibody-drug Conjugate for Cancer Market Share by Country (2020-2031)
 Figure 20. United States Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Antibody-drug Conjugate for Cancer Market Share by Country (2020-2031)
 Figure 24. Germany Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. France Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. U.K. Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Italy Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Russia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Nordic Countries Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Antibody-drug Conjugate for Cancer Market Share by Region (2020-2031)
 Figure 32. China Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Japan Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. South Korea Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Southeast Asia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. India Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Australia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Antibody-drug Conjugate for Cancer Market Share by Country (2020-2031)
 Figure 40. Mexico Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Brazil Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Antibody-drug Conjugate for Cancer Market Share by Country (2020-2031)
 Figure 44. Turkey Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Saudi Arabia Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. UAE Antibody-drug Conjugate for Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Gilead Sciences Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2020-2025)
 Figure 48. Roche Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2020-2025)
 Figure 49. Pfizer Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2020-2025)
 Figure 50. Takeda Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2020-2025)
 Figure 51. Seagen Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2020-2025)
 Figure 52. Innate Pharma Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2020-2025)
 Figure 53. AstraZeneca Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2020-2025)
 Figure 54. GSK Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2020-2025)
 Figure 55. Rakuten Medical Revenue Growth Rate in Antibody-drug Conjugate for Cancer Business (2020-2025)
 Figure 56. Bottom-up and Top-down Approaches for This Report
 Figure 57. Data Triangulation
 Figure 58. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Antibody drug Conjugates Market Insights Forecast to 2030
Global Antibody drug Conjugates for Tumors Market Research Report 2024
Global Antibody drug Conjugates ADCs CMO and CDMO Market Research Report 2025
Global Antibody Drug Conjugate CDMO Market Research Report 2024
Global ADC Linkers Market Research Report 2024
Global HER2 Antibody Drug Conjugate Market Research Report 2025
Global Monoclonal Antibody ADC Drugs Market Research Report 2025
Global Antibody Drug Conjugates Contract Manufacturing Market Research Report 2025
Global Antibody drug Conjugate ADC Payload Market Research Report 2025
Antibody Drug Conjugate ADC Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global HER2 ADC Drugs Market Research Report 2024
Global Highly Potent API HPAPI For Antibody drug Conjugate ADC Market Research Report 2025
Global ADC Manufacturing Service Market Research Report 2025
Global Cancer Antibody Drug Conjugates Market Research Report 2024
Global Antibody radionuclide Conjugates Market Research Report 2024
Global ADC Drug CDMO Service Market Research Report 2024
Global Monoclonal Antibody Drugs for Cancer Market Research Report 2024
Global Conjugated Monoclonal Antibodies Market Research Report 2024
Global Therapeutic Monoclonal Antibodies Drug Market Research Report 2024
Global Therapeutic Monoclonal Antibodies Market Research Report 2024

RELATED REPORTS

Global Fixation Device for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4H16852
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Group A Streptococcus for Injection Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37K16619
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Boron Neutron Capture Therapy System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30U16301
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Radioactive Glass Microsphere Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-2G16953
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions